Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,555 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Clear all
Terminated Phase 1 Interventional

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

NCT01143545
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

NCT00589602
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 7, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

NCT06285422
View directory record Official record
Conditions
Non Hodgkin's Lymphoma, Large B-cell Lymphoma
Interventions
SC262
Drug
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Kansas City, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ExoFlo for the Treatment of Perianal Fistulas

NCT05836883
View directory record Official record
Conditions
Perianal Fistula, Crohn's Disease
Interventions
ExoFlo, Local injection of normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

NCT04679194
View directory record Official record
Conditions
AML/MDS
Interventions
Mana 312
Biological
Lead sponsor
Mana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

NCT00948922
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Melphalan, Autologous Stem Cell Transplant, Fludarabine, Allogeneic Stem Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

NCT02150551
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Allogeneic bone marrow-derived mesenchymal stromal cells
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
12 Years to 22 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

NCT02504619
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
CordIn
Biological
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Oakland, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 7, 2026, 7:33 PM EDT
Active, not recruiting Not applicable Interventional

Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

NCT05690971
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Interventions
App, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

NCT00002547
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, cytarabine, methotrexate, allogeneic bone marrow transplantation, syngeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Stress Management Among Allogeneic HCT Caregivers

NCT05078229
View directory record Official record
Conditions
Burden, Stress
Interventions
FOCUS, Healthy Living
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
21 Years and older
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

NCT00048100
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Apheresis, Stem Cell Transplant
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 7, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

NCT02677064
View directory record Official record
Conditions
Acute Leukemia, Newly Diagnosed, Relapsed
Interventions
assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Hartford, Connecticut • New York, New York • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

NCT00006233
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

NCT00060424
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

NCT00727441
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreatic cancer vaccine, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

NCT04317781
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Tagraxofusp-erzs
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 7, 2026, 7:33 PM EDT
Not listed No phase listed Observational

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00005900
View directory record Official record
Conditions
I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Niemann-Pick Disease, Pulmonary Complications, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Metachromatic Leukodystrophy, Gaucher's Disease, Wolman Disease
Interventions
Not listed
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

NCT00003153
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00054353
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
fludarabine phosphate, melphalan, total-body irradiation, mycophenolate mofetil, cyclosporine, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 7, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

NCT01622556
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Fludarabine, Busulfan, Thymoglobulin, Total Body Irradiation, Umbilical Cord Blood
Drug · Radiation · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

NCT02108522
View directory record Official record
Conditions
Infection
Interventions
Multivirus Specific T cells
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 7, 2026, 7:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

NCT05531786
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Administration of Virus-Specific Cytotoxic T-Lymphocytes

NCT00590083
View directory record Official record
Conditions
Adenovirus Infection
Interventions
CTL administration
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 7, 2026, 7:33 PM EDT